DOCSLIB.ORG

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody Published OnlineFirst August 27, 2019; DOI: 10.1158/1078-0432.CCR-19-1090 Clinical Trials: Immunotherapy Clinical Cancer Research A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors Toshihiko Doi1, Kei Muro2, Hiroshi Ishii3, Terufumi Kato4, Takahiro Tsushima5, Mitsuhiro Takenoyama6, Satoshi Oizumi7, Kazuto Gemmoto8, Hideaki Suna8, Kouki Enokitani9, Tetsuyoshi Kawakami9, Hiroyoshi Nishikawa10,11, and Noboru Yamamoto12 Abstract Purpose: Regulatory T cells (Tregs) expressing CC chemo- part and 90 in the expansion part. No dose-limiting kine receptor 4 (CCR4) can suppress antitumor immune toxicities were observed in the dose-escalation part. Grade responses and are associated with poor prognoses in several 3/4 treatment-related adverse events (TRAEs) occurred in cancers. We assessed the safety and efficacy of combined 29% of patients in the expansion part (no grade 5 TRAEs). mogamulizumab (anti-CCR4 antibody) and nivolumab The most frequent TRAEs were rash (39%), rash maculopap- [anti-programmed death-1 (PD-1) antibody] in immunother- ular (20%), diarrhea (13%), stomatitis (12%), and pruritus apy-na€ve patients with advanced/metastatic solid tumors. (11%). There were four (27%) confirmed tumor responses Patients and Methods: This study (NCT02476123) com- among 15 patients with hepatocellular carcinoma, and prised dose-escalation (3þ3 design) and expansion parts. one confirmed and two unconfirmed responses among 15 Patients received nivolumab (3.0 mg/kg) every 2 weeks, with patients with pancreatic adenocarcinoma. During treatment, þ À mogamulizumab (0.3 or 1.0 mg/kg in dose escalation, populations of effector Tregs (CD4 CD45RA FoxP3high) þ 1.0 mg/kg in expansion) once weekly for 4 weeks, then every decreased and CD8 T cells in tumor-infiltrating lymphocytes 2 weeks, until progression or unacceptable toxicity. Primary increased. objective was safety; secondary objectives were antitumor Conclusions: Combining an anti–PD-1 antibody, nivo- effects, pharmacokinetics, and immunogenicity. Exploratory lumab, with a Treg-depleting anti-CCR4 antibody, moga- biomarker analyses were conducted. mulizumab, provides an acceptable safety profile, antitu- Results: Ninety-six patients were enrolled (July mor activity, and a potentially effective option in cancer 2015ÀNovember 2016): six patients in the dose-escalation immunotherapy. Introduction 1Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan. 2Clinical Oncology and Outpatient Treatment Center, Aichi The immune checkpoint programmed death-1 (PD-1) receptor Cancer Center Hospital, Nagoya, Japan. 3Clinical Research Center, National and its ligand PD-L1 suppress antitumor immunity. Nivolumab, a 4 Hospital Organization Shikoku Cancer Center, Matsuyama, Japan. Division of human IgG4 anti–PD-1 mAb, has been shown in randomized 5 Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. Division of GI controlled studies to provide clinical benefits in patients with Oncology, Shizuoka Cancer Center, Shizuoka, Japan. 6Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, various tumors, and is associated with health-related quality-of- Japan. 7Department of Respiratory Medicine, National Hospital Organization life improvement in patients with advanced melanoma and Hokkaido Cancer Center, Sapporo, Japan. 8Oncology Clinical Development Unit, advanced renal cell carcinoma (1–3). However, it has recently Ono Pharmaceutical Co., Ltd., Osaka, Japan. 9R&D Division, Kyowa Kirin Co., Ltd., been reported that primary, adaptive, or acquired resistance to 10 Tokyo, Japan. Department of Immunology, Nagoya University Graduate anti–PD-1/PD-L1 therapy may be partially mediated by regula- 11 School of Medicine, Nagoya, Japan. Division of Cancer Immunology, Research tory T cells (Tregs; ref. 4), and that these Tregs inhibit immune Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), Nation- al Cancer Center, Tokyo, Japan. 12Department of Experimental Therapeutics, responses against tumors (5). National Cancer Center Hospital, Tokyo, Japan. Mogamulizumab is a humanized IgG1 mAb targeting the CC chemokine receptor 4 (CCR4) that has a defucosylated Fc region, Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). which enhances the antibody-dependent cellular cytotoxicity (ADCC; ref. 6), and has been approved for T-cell lymphomas by Corresponding Author: Toshihiko Doi, National Cancer Center Hospital East, the Pharmaceuticals and Medical Devices Agency, Food and Drug 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba-ken 277-8577, Japan. Phone: 814-7133- 1111; Fax: 814-7131-9960; E-mail: [email protected] Administration, and European Medicines Agency. The tolerabil- ity, safety, and antitumor activity of mogamulizumab against Clin Cancer Res 2019;XX:XX–XX CCR4-expressing T-cell lymphomas accompanied by the rapid doi: 10.1158/1078-0432.CCR-19-1090 and long-lasting depletion of peripheral Tregs have been con- Ó2019 American Association for Cancer Research. firmed in multiple clinical trials (7–9). In anticipation of this www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst August 27, 2019; DOI: 10.1158/1078-0432.CCR-19-1090 Doi et al. confirmed solid tumors; had progressed, been intolerant to any Translational Relevance standard treatment regimen, or had refused standard therapy; It was widely known that PD-1/PD-L1 inhibitors have were at least 20 years old; had measurable disease based on the encouraging clinical activity in several cancers and that Tregs revised Response Evaluation Criteria In Solid Tumors (RECIST) are key cells that affect the immunosuppressive tumor micro- guidelines version 1.1; had Eastern Cooperative Oncology Group environment. Before this study, there was no clinical evidence performance status score of 0 or 1; had adequate hematologic, regarding the combination of Treg depletion and an anti–PD- renal, hepatic, and respiratory functions; and had a life expectancy 1/PD-L1 antibody in patients with solid tumors. To our of at least 3 months. Key exclusion criteria were previous treatment knowledge, this is the first clinical report to provide evidence with antibodies or drugs that target T-cell costimulation or check- for the mechanism of tumor immunity activation by Treg point pathways, or with mogamulizumab. Patients who were depletion in the tumor microenvironment. Combination pregnant or lactating, or who had uncontrolled central nervous therapy with mogamulizumab and nivolumab resulted in a system metastases or known carcinomatous meningitis, were not þ clear depletion of effector Tregs and the expansion of CD8 eligible. Patients with HCC were required to have Child-Pugh T cells in tumor-infiltrating lymphocytes. In addition, a man- scores of 5 or 6 (Child-Pugh A). Patients infected with hepatitis B ageable safety profile and several tumor responses were virus (HBV) (HBs antigen positive) were excluded because of a observed in patients with solid tumors. These results provide potential risk of HBV reactivation by mogamulizumab (16). clinical evidence for the safety and potential efficacy of moga- This study was conducted in accordance with the Declaration of mulizumab and nivolumab combination therapy, as well as Helsinki and the Good Clinical Practice guidelines (GCP) and is the potential role of biomarkers in mediating the antitumor registered at ClinicalTrials.gov (identifier NCT02476123). The effects. study protocol and amendments were approved by the institu- tional review board of each participating institute, and written informed consent was obtained from all patients before conduct- ing any study-related procedures. antitumor activity by the depletion of Tregs, a phase I study of mogamulizumab monotherapy in patients with solid cancers was Procedures performed and a reduction in peripheral Tregs was clearly Patients were enrolled in a 3þ3 design and received nivolumab observed (10). (3.0 mg/kg) intravenously every 2 weeks and mogamulizumab at High levels of tumor-infiltrating effector Tregs are associated 0.3 mg/kg (cohort 1) or 1.0 mg/kg (cohort 2) in the dose- with poor clinical prognoses in some solid tumors (11). More- escalation part and 1.0 mg/kg in the expansion part weekly during þ À over, effector Tregs, which are defined by CD4 CD45RA Fork- cycle 1 and subsequently every 2 weeks until disease progression head box protein P3 (FoxP3)high that highly expresses CCR4, have or unacceptable toxicity. Each cycle lasted 28 days, and the the highest suppressive effects on antitumor immune responses in duration of a cycle was extended in the case of dose delays (the peripheral blood and the tumor microenvironment (TME; criteria for dose delays are provided in the Supplementary Data). ref. 12). According to a previous clinical study, patients with Oral antihistamine and acetaminophen were administered as melanoma who progressed after treatment with nivolumab and premedication before each dose, and a systemic corticosteroid a multipeptide vaccine had increased Tregs in peripheral blood was administered intravenously prior to the first dose of moga- compared with those who did not have progressive disease (13). mulizumab to prevent infusion-related reactions. Patients were Interestingly, a recent preclinical study suggested
Load more

Recommended publications
  • T Cell Binding to Activated Dendritic Cells Cutting Edge
    Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang and Sam T. Hwang This information is current as J Immunol 2001; 167:4791-4795; ; of September 27, 2021. doi: 10.4049/jimmunol.167.9.4791 http://www.jimmunol.org/content/167/9/4791 Supplementary http://www.jimmunol.org/content/suppl/2001/10/11/167.9.4791.DC1 Downloaded from Material References This article cites 32 articles, 13 of which you can access for free at: http://www.jimmunol.org/content/167/9/4791.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. ● Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells Meng-tse Wu, Hui Fang, and Sam T. Hwang1 DC. In the periphery, activated, Ag-bearing DC may bind to cog- The binding of a T cell to an Ag-laden dendritic cell (DC) is a nate effector memory T cells (mTC).
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Chemokine Receptors in Allergic Diseases Laure Castan, A
    Chemokine receptors in allergic diseases Laure Castan, A. Magnan, Grégory Bouchaud To cite this version: Laure Castan, A. Magnan, Grégory Bouchaud. Chemokine receptors in allergic diseases. Allergy, Wiley, 2017, 72 (5), pp.682-690. 10.1111/all.13089. hal-01602523 HAL Id: hal-01602523 https://hal.archives-ouvertes.fr/hal-01602523 Submitted on 11 Jul 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - ShareAlike| 4.0 International License Allergy REVIEW ARTICLE Chemokine receptors in allergic diseases L. Castan1,2,3,4, A. Magnan2,3,5 & G. Bouchaud1 1INRA, UR1268 BIA; 2INSERM, UMR1087, lnstitut du thorax; 3CNRS, UMR6291; 4Universite de Nantes; 5CHU de Nantes, Service de Pneumologie, Institut du thorax, Nantes, France To cite this article: Castan L, Magnan A, Bouchaud G. Chemokine receptors in allergic diseases. Allergy 2017; 72: 682–690. Keywords Abstract asthma; atopic dermatitis; chemokine; Under homeostatic conditions, as well as in various diseases, leukocyte migration chemokine receptor; food allergy. is a crucial issue for the immune system that is mainly organized through the acti- Correspondence vation of bone marrow-derived cells in various tissues. Immune cell trafficking is Gregory Bouchaud, INRA, UR1268 BIA, rue orchestrated by a family of small proteins called chemokines.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Biologic Armamentarium in Psoriasis
    Vol 9, Issue 1, 2016 ISSN - 0974-2441 Review Article BIOLOGIC ARMAMENTARIUM IN PSORIASIS GANESH PAI1*, NITHIN SASHIDHARAN2 1Medical Director, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. 2Consultant Clinical Pharmacologist, Derma-Care ‘The Trade Centre’, Mangalore - 575 003, Karnataka, India. Email: [email protected] Received: 14 July 2015, Revised and Accepted: 24 August 2015 ABSTRACT Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition serving as a global burden. A moderate to severe psoriasis can be treated with conventional therapies. Less efficacy, poor patient compliance, and toxicity issues were the major problems associated with conventional therapies. The introduction of biologic therapy has a great impression on psoriatic treatment duration and enhanced quality of life in psoriasis patients. The new biologic therapies are tailor-made medications with the goal of more specific and effective treatment; less toxicity. The biologic therapy is aimed to target antigen presentation and co-stimulation, T-cell activation, and leukocyte adhesion; and pro-inflammatory cascade. They act as effective and safer substitute to traditional therapy. Secukinumab, certolizumab, itolizumab, golimumab, ustekinumab, adalimumab, infliximab etanercept, alefacept, etc. are the approved biologic with the global market. This review briefs about psoriasis pathogenesis, traditional treatments, and biologic therapies potential. Keywords: Psoriasis, Biologic, Non-biologic treatment. INTRODUCTION migration, potentiation of Th1 type of response, angiogenesis, and epidermal hyperplasia [7]. Psoriasis is an autoimmune disease and further classed as a chronic inflammatory skin condition with prevalence ranging 1-3% in the TNF- is plays vital role in the pathogenesis of psoriasis. It acts by world [1].
    [Show full text]
  • Safety and Efficacy Profile of Mogamulizumab (Poteligeo)
    Zhang et al. BMC Cancer (2021) 21:618 https://doi.org/10.1186/s12885-021-08363-w RESEARCH ARTICLE Open Access Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies Ting Zhang1,2†, Jing Sun3†, Jinying Li4, Yunuo Zhao1,2, Tao Zhang1,2, Ruoning Yang1,2 and Xuelei Ma1* Abstract Background: CC chemokine receptor 4 (CCR4), the receptor for CCL22 and CCL17, is expressed on the surface of effector Tregs that have the highest suppressive effects on antitumor immune response. CCR4 is also widely expressed on the surface of tumor cells from patients with adult T-cell leukemia/lymphoma (ATL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Mogamulizumab is a humanized, IgG1 kappa monoclonal antibody that is directed against CCR4. By reducing the number of CCR4-positive Tregs and tumor cells, the mogamulizumab can reduce tumor burden and boost antitumor immunity to achieve antitumor effects. Methods: We examined the PubMed and ClinicalTrials.gov until 1 February 2020. Considering variability in different studies, we selected the adverse events (AEs), overall survival (OS), progression-free survival (PFS), objective responses rate (ORR) and Hazard Ratio (HR) for PFS to evaluate the safety and efficacy profile of mogamulizumab. Results: When patients were treated with mogamulizumab monotherapy, the most common all-grade AEs were lymphopenia, infusion reaction, fever, rash and chills while the most common grade ≥ 3 AEs were lymphopenia, neutropenia and rash. When patients were treated with combined therapy of mogamulizumab and other drugs, the most common all-grade AEs were neutropenia, anaemia, lymphopenia and gastrointestinal disorder, while the most common grade ≥ 3 AEs was lymphopenia.
    [Show full text]
  • New Drug Arrivals Q 4 – Monograph Summary
    Centene Pharmacy & Therapeutics Committee New Drug Arrivals Summary 4Q18 – Survey Meeting Review Type (RT) Descriptions 1, 2, 3, or 5 Review type 1 (RT1): New Drug Review Full review of new chemical or biologic agents Review type 2 (RT2): New Indication Review Abbreviated review of new dosage forms of existing agents that are approved for a new indication or use Review type 5 (RT5): Abbreviated Reviews for Intravenous Chemotherapy Agents Abbreviated review for intravenous chemotherapy agents which are usually covered under the medical benefit Type Drug Name FDA-Approved Indication(s) RT1 Avatrombopag (Doptelet®) Doptelet is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. RT1 Baricitinib Olumiant is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or (Olumiant® ) more tumor necrosis factor (TNF) antagonist therapies (TNFi). RT1 Elagolix (Orilissa®) For the management of moderate-to-severe pain associated with endometriosis RT1 Ivosidenib For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as (Tibsovo®) detected by an FDA-approved test RT1 Migalastat (Galafold™) Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. RT1 Moxidectin Moxidectin is an anthelmintic indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older. RT1 Patisiran (Onpattro™) Onpattro is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
    [Show full text]
  • HIV-1 Tat Protein Mimicry of Chemokines
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 13153–13158, October 1998 Immunology HIV-1 Tat protein mimicry of chemokines ADRIANA ALBINI*, SILVANO FERRINI*, ROBERTO BENELLI*, SABRINA SFORZINI*, DANIELA GIUNCIUGLIO*, MARIA GRAZIA ALUIGI*, AMANDA E. I. PROUDFOOT†,SAMI ALOUANI†,TIMOTHY N. C. WELLS†, GIULIANO MARIANI‡,RONALD L. RABIN§,JOSHUA M. FARBER§, AND DOUGLAS M. NOONAN*¶ *Centro di Biotecnologie Avanzate, Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132 Genoa, Italy; †Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, 14 chemin des Aulx, 1228 Plan-les Ouates, Geneva, Switzerland; ‡Dipartimento di Medicina Interna, Medicina Nucleare, University of Genova, Viale Benedetto XV, 6, 16132 Genoa, Italy; and §National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N228 MSC 1888, Bethesda, MD 20892 Edited by Anthony S. Fauci, National Institute of Allergy and Infectious Diseases, Bethesda, MD, and approved August 25, 1998 (received for review June 24, 1998) ABSTRACT The HIV-1 Tat protein is a potent chemoat- ceptors for some dual tropic HIV-1 strains (10, 11). A CCR2 tractant for monocytes. We observed that Tat shows conserved polymorphism has been found to correlate with delayed amino acids corresponding to critical sequences of the che- progression to AIDS (12, 13). mokines, a family of molecules known for their potent ability We report here that the HIV-1 Tat protein and the peptide to attract monocytes. Synthetic Tat and a peptide (CysL24–51) encompassing the cysteine-rich and core regions induce per- encompassing the ‘‘chemokine-like’’ region of Tat induced a tussis toxin sensitive Ca21 fluxes in monocytes.
    [Show full text]
  • Keeping up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A
    Keeping Up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A. Shlom, PharmD, BCPS Senior Vice President & Director Clinical Pharmacy Program | Acurity, Inc. Privileged and Confidential April 10, 2019 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ▪ Identify orphan drugs and first-in-class medications approved by the FDA in 2018. ▪ List five new drugs and their indications. ▪ Identify the place in therapy for three novel monoclonal antibodies. ▪ Discuss at least two new medications that address public health concerns. Dr. Shlom does not have any conflicts of interest in regard to this presentation. Both trade names and generic names will be discussed throughout the presentation Privileged and Confidential 2018 NDA Approvals (NMEs/BLAs) ▪ Lutathera (lutetium Lu 177 dotatate) ▪ Braftovi (encorafenib) ▪ Vizimpro (dacomitinib) ▪ Biktarvy (bictegravir, emtricitabine, ▪ TPOXX (tecovirimat) ▪ Libtayo (cemiplimab-rwic) tenofovir, ▪ Tibsovo (ivosidenib) ▪ Seysara (sarecycline) alafenamide) ▪ Krintafel (tafenoquine) ▪ Nuzyra (omadacycline) ▪ Symdeko (tezacaftor, ivacaftor) ▪ Orilissa (elagolix sodium) ▪ Revcovi (elapegademase-lvir) ▪ Erleada (apalutamide) ▪ Omegaven (fish oil triglycerides) ▪ Tegsedi (inotersen) ▪ Trogarzo (ibalizumab-uiyk) ▪ Mulpleta (lusutrombopag) ▪ Talzenna (talazoparib) ▪ Ilumya (tildrakizumab-asmn) ▪ Poteligeo (mogamulizumab-kpkc) ▪ Xofluza (baloxavir marboxil) ▪ Tavalisse (fostamatinib disodium) ▪ Onpattro (patisiran)
    [Show full text]
  • Comprehensive Identification of Genes Driven by ERV9-Ltrs Reveals TNFRSF10B As a Re-Activatable Mediator of Testicular Cancer Cell Death
    Cell Death and Differentiation (2016) 23, 64–75 & 2016 Macmillan Publishers Limited All rights reserved 1350-9047/16 www.nature.com/cdd Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death U Beyer1,2,5, SK Krönung1,5, A Leha3, L Walter4 and M Dobbelstein*,1 The long terminal repeat (LTR) of human endogenous retrovirus type 9 (ERV9) acts as a germline-specific promoter that induces the expression of a proapoptotic isoform of the tumor suppressor homologue p63, GTAp63, in male germline cells. Testicular cancer cells silence this promoter, but inhibitors of histone deacetylases (HDACs) restore GTAp63 expression and give rise to apoptosis. We show here that numerous additional transcripts throughout the genome are driven by related ERV9-LTRs. 3' Rapid amplification of cDNA ends (3’RACE) was combined with next-generation sequencing to establish a large set of such mRNAs. HDAC inhibitors induce these ERV9-LTR-driven genes but not the LTRs from other ERVs. In particular, a transcript encoding the death receptor DR5 originates from an ERV9-LTR inserted upstream of the protein coding regions of the TNFRSF10B gene, and it shows an expression pattern similar to GTAp63. When treating testicular cancer cells with HDAC inhibitors as well as the death ligand TNF-related apoptosis-inducing ligand (TRAIL), rapid cell death was observed, which depended on TNFRSF10B expression. HDAC inhibitors also cooperate with cisplatin (cDDP) to promote apoptosis in testicular cancer cells. ERV9-LTRs not only drive a large set of human transcripts, but a subset of them acts in a proapoptotic manner.
    [Show full text]
  • Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3+ Regulatory T Cells
    Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3+ Regulatory T Cells This information is current as Hyung W. Lim, Jeeho Lee, Peter Hillsamer and Chang H. of September 28, 2021. Kim J Immunol 2008; 180:122-129; ; doi: 10.4049/jimmunol.180.1.122 http://www.jimmunol.org/content/180/1/122 Downloaded from References This article cites 44 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/180/1/122.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Human Th17 Cells Share Major Trafficking Receptors with Both Polarized Effector T Cells and FOXP3؉ Regulatory T Cells1 Hyung W. Lim,* Jeeho Lee,* Peter Hillsamer,† and Chang H. Kim2* It is a question of interest whether Th17 cells express trafficking receptors unique to this Th cell lineage and migrate specifically to certain tissue sites.
    [Show full text]
  • On the Horizon: Immuno-Oncology (I-O) Combinations
    Immuno-Oncology (I-O) Combinations • Jeffrey A. Sosman, MD • Robert H. Lurie Comprehensive Cancer Center of Northwestern University The Cancer–Immunity Cycle Daniel Chen and Ira Mellman Immunity, Volume 39, Issue 1, 2013, 1 - 10 The Cancer–Immunity Cycle Daniel Chen and Ira Mellman Immunity, Volume 39, Issue 1, 2013, 1 - 10 Stimulatory and Inhibitory Factors in the Cancer-Immunity Cycle Each step of the Cancer-Immunity Cycle requires the coordination of numerous factors, both stimulatory and inhibitory in nature. Stimulatory factors shown in green promote immunity, ... Where will Improvements come from? • Combinations: – Based on Template: anti-PD-1/PD-L1 or with anti-PD- 1/anti-CTLA-4 • Block other co-inhibitory: LAG3, TIM3, KIR, VISTA • Activate co-stimulatory: 4-1BB, OX-40, GITR, CD27, ICOS • Block inhibitory molecules- IDOi, TGFbi, CSF1Ri, anti-IL-6 or anti- IL-10 • Effect trafficking- anti-VEGF, CCL5, CXCR4i • Vaccines- TVEC- oncolytic virus, Neoantigen, other cellular • Adoptive Cellular therapy- TIL, CAR-T cells, TCR T-cells Where will Improvements come from? • Combinations: – Based on Template: anti-PD-1/PD-L1 or with anti-PD- 1/anti-CTLA-4 • Signal Inhibition, BRAF directed (BRAFi+MEKi), MEKi, PI3K inhibition (PTEN effects) • Cytokines- IL-2, IFN a,b,g,, Directed cytokines (FAP-IL-2v or CEA-IL-2v) • Epigenetic modulation- gene expression and EVR expression • Microbiome modification- fecal transplants • Chemotherapy other cytotoxics • Localized Irradiation SBRT, SRS T cells in Tumors Express Multiple Immunoinhibitory Receptors
    [Show full text]